Atlas Molecular Pharma, a biotech company specializing in the discovery of first-in-class therapies for rare and ultra-rare diseases, has secured $3.5 million in new funding. Founded in 2015 as a spin-off of CIC bioGUNE, the company leverages its proprietary Chassys Platform® to identify pharmacological chaperones. These chaperones are designed to stabilize defective enzymes and restore their function, addressing severe metabolic disorders that currently lack effective treatments.
The company's lead candidate, ATL-001, is currently in clinical development for Congenital Erythropoietic Porphyria (CEP), an ultra-rare metabolic disease for which no existing therapies are available. This investment round underscores confidence in Atlas Molecular Pharma's innovative approach to drug discovery and its commitment to addressing significant unmet medical needs. The capital infusion is expected to accelerate key development milestones for its pipeline.
Atlas Molecular Pharma plans to deploy the newly raised capital to advance the clinical development of ATL-001. A portion of the funds will also be allocated to further expand its drug discovery pipeline, utilizing the Chassys Platform® to identify additional novel drug candidates. These strategic investments are aimed at strengthening the company's position in the rare disease therapeutic landscape and supporting its operational growth initiatives.
Looking ahead, Atlas Molecular Pharma is focused on its vision to become a trusted innovation partner in rare disease drug discovery. The company is committed to delivering hope and life-changing treatments to underserved patient communities, and this funding round provides crucial resources to support its ongoing efforts to bring innovative solutions to patients living with rare and ultra-rare conditions.
.png&w=3840&q=75)
